Introduction
Autologous as well as allogeneic BMT contributes significantly to the therapeutic options for children who suffer from refractory or relapsing neoplasia, as well as from chronic BM failure. Hematopoietic SCT (HSCT) is a professional medical activity, which, similar to other specialties, led to the development of groups of individuals with similar or overlapping interests, including the Polish Pediatric SCT Group (PPSCTG). The PPSCTG carries out activities for education, professional standards, production of guidelines, lobbying, collection analysis and reports the outcomes of all transplants performed by Polish member centres. HSCT is a rapidly evolving field, with the discovery in recent years of new indications for the procedure and the development of new transplant techniques where alternative hematopoietic stem cell sources are now widely used in place of BM from related and unrelated donors.
Over the last three decades, great progress in childhood HSCT has been made because of the successes of basic science, diagnostic procedures and modern therapy. Thousands of patients have already received treatment for classical indications such as malignancy, marrow insufficiency and congenital diseases, and positive results obtained in these disorders are well documented. Good quality of life during and after HSCT seems to be very important. Bioethics is understood to be the disciplined study of morality in biological sciences including childhood HSCT. 1 
Ethical problems concerning transplantation procedure
Ethical problems can occur in every phase of the complex transplantation procedure: pre-transplantation care, donor search, harvest, transplantation phase (which includes the preparative regimen, cell infusion and hospitalization until the patient has recovered from neutropenia), short-term follow-up care (1-3 months) and long-term follow-up care. However, SCT is associated with a substantial risk of lifethreatening acute complications as well as significant chronic organ toxicity. In some patients, SCT-related complications are superimposed on pre-existing chronic organ insufficiency, such as renal insufficiency related to previous nephrotoxic treatment. In addition, almost all patients entering SCT treatment show significant immunosuppression, either because of cytostatic or immunosuppressive pretreatment or as a result of their underlying disease. These pre-existing factors, as well as SCT-related parameters such as the toxicity of the conditioning regimen, infection or GVHD, may all contribute to the clinical course after SCT and ultimately determine outcome.
HSCT is typically performed for patients with lifethreatening diseases and malignancies, often in an advanced stage. HSCT is frequently a patient's last chance for life. BMT involves substantial risks, but it is typically performed with curative intent. Selection of candidates for hematopoietic transplantation is another area of tension between transplant centers and the maternal centers for children and should be done according to international guidelines. During the pre-transplantation process, decisions must be made regarding the type of transplant needed: autologous, syngeneic or allogeneic. The high cost per patient of HSCT causes this therapy to be the focus of much controversy, given the competing societal demands to provide all possible therapy to preserve life while simultaneously limiting global health-care expenditures. Treatment and eligibility decisions for HSCT are often heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility providers and patients. Last but not least, a bioethical problem is that approaches to gene transfer and therapy can use transplantation methodologies and augment their effects. [2] [3] [4] HSCT in childhood and clinical research HSCT in childhood is an area for clinical research. The goals of research, though important, should never be permitted to override the health, well-being and care of research participants. They try to do that through the ethical and scientific standards for carrying out biomedical research on human subjects, which have been developed and established in international guidelines. HSCT in childhood is not an active area for clinical research such as HSCT in adults. Several high-cost pharmacy items have now come into the transplant arena. Most of the new, very promising drugs are tested only in adults. These include new drugs for the preparative regimen, such as rituximab, gemtuzumab, ozogamicin, ibritumomab, tiuxetan and trastuzumab. Registration of drugs often takes a long time but children may be more vulnerable to any kind of experiment and we have to be very careful in starting research with children.
Stem cell plasticity and transplantation
The other ethical problem with HSCT is that recent observations demonstrating hematopoietic stem cell plasticity point toward their use in repairing extra hematological tissues and herald a new era of research and clinical application. The European experience has been formulated in several guidelines. The most important are as follows: the research of adult and embryonic stem cells should be progressed; reproductive cloning is forbidden in most European countries; therapeutic cloning in which the nucleus of somatic cells is transferred to oocyte has potential for therapy. For this reason, European Science Foundation suggest, but under strong regulatory control by national bodies, that there are many important scientific questions that control human stem cell research. This careful statement, leaving space for gathering new facts, was accepted by many researchers. In the United States, the use of embryonic stem cells in research was not allowed, but in August 2001 President George Bush decided to create a special fund for stem cell study. On this occasion, the National Academy of Sciences published a statement: 'Public funding for research on human stem cells-both embryonic and adult should be generousy Current research shows that embryonic hold far more potential than adult cells'. Thus, in the United States the door for research on embryonic stem cell has carefully opened, but clinical trials should proceed under special permission. 5 
Conflict of interest
In recent times, conflict of interest has emerged as one of the most serious ethical problems facing the international community. In fact, this is a question that affects not just programming and development of medical research and science but the well-being of people and the very dignity and prestige of scientific learning itself. Today, this conflict is obvious in a number of specific ways. First, it can arise between economic interest on the one hand and medicine and health care on the other. The majority of biomedical research has been predominantly motivated by concern for the benefit of already privileged communities. This is reflected in the fact that World Health Organization estimated that 90% of the resources devoted to research and development on medical problems are applied to diseases causing less than 10% of the present global suffering. Second, it can be seen in the selection of research programs, where those programs that hold out the promise of a quick profit are often preferred to other research that involves higher costs and greater investment of time because it respects the demands of ethics and justice. 6 One example of such conflict of interest is the way in which priorities are set for pharmaceutical research. In some developed countries, for instance, huge sums are spent on producing medicines that serve hedonistic purposes, or in marketing different brands of already available and equally effective drugs, whereas in poorer areas of the world many of the drugs are not available for the treatment of devastating and life-threatening diseases. In these countries, access to even the most basic medicines is almost impossible because the profit motive is absent.
Another example of conflict of interest in HSCT is the right to permit the publication of research data depending on whether or not such data are in the interest of the sponsoring groups.
Public authorities, such as the Council of Europe, have a function in ensuring that research is directed to the good of people and of society, and in tempering and reconciling the pressures of divergent interests. They try to do that through the ethical and scientific standards for carrying out biomedical research on human subjects, which have been developed and established in international guidelines, including: All international guidelines require the ethical and scientific review of biomedical research alongside informed consent and the appropriate protection of those unable to consent as essential measures to protect the individual person and the communities who participate in research. 5, 7 The purpose of an Ethical Committe (EC) in reviewing biomedical research is to contribute to safeguarding the dignity, rights, safety and well-being of all actual or potential research participants. A cardinal principle of research involving human participants is 'respect for the dignity of persons'. The goals of research, though important, should never be permitted to override the health, well-being and care of research participants. ECs should also take into consideration the principle of justice. Justice requires that the benefits and burdens of research be distributed fairly among all groups and classes in society, taking into account age, gender, economic status, culture and ethnic considerations.
ECs should provide independent, competent and timely review of the ethics of proposed studies. In their composition, procedures and decision-making, ECs need to have independence from political, institutional, professional and market influences. They similarly need to demonstrate competence and efficiency in their work.
ECs are responsible for carrying out the review of the proposed research before the commencement of the research. They also need to ensure that there is regular evaluation of the ethics of ongoing studies that received a positive decision.
ECs are responsible for acting in the full interests of potential research participants and concerned communities, taking into account the interests and needs of the researchers, and having due regard for the requirements of relevant regulatory agencies and applicable laws.
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Conclusion
The expectation of patients concerning the new way of treatment is certainly an important motivation for researchers and physicians. Societies in Europe seem to accept the idea of use of their own or allogeneic stem cells for tissue engineering and transplantation. We hope that these expectations will be accomplished in our time.
